Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.14 Analyst target: $20.30 Upside: 546.50%
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.